Do analysts prefer ANEB or MCRB?

Seres Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 221.17%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Seres Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ANEB or MCRB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Seres Therapeutics N/A -130.29% -35.35%

Do analysts prefer XBIT or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, XBIT or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is XBIT or ANEB more profitable?

XBiotech's return on equity of -26.10% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts rate ANEB or BTMD?

biote has a consensus target price of $2.75, indicating a potential upside of 16.53%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 biote 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate ANEB or ACRV?

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 652.69%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has better earnings & valuation, ANEB or ACRV?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A

Is ANEB or ACRV more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Acrivon Therapeutics N/A -64.43% -57.08%

Do analysts prefer ANVS or ANEB?

Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, ANVS or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is ANVS or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Anebulo Pharmaceuticals (ANEB) Competitors

$0.40 +0.02 (+6.64%)

As of 01:26 PM Eastern

Compare

ANEB vs. MCRB, XBIT, BTMD, ACRV, and ANVS

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? MarketBeat compares Anebulo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anebulo Pharmaceuticals include Seres Therapeutics (MCRB), XBiotech (XBIT), biote (BTMD), Acrivon Therapeutics (ACRV), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry.

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Anebulo Pharmaceuticals has a beta of -1.88, indicating that its share price is 288% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Seres Therapeutics	N/A	-130.29%	-35.35%

In the previous week, Seres Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Seres Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Seres Therapeutics' average media sentiment score of 0.94 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Seres Therapeutics	Positive

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Seres Therapeutics	$790K	83.93	$5.70M	-$5.17	N/A

Seres Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 221.17%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Seres Therapeutics beats Anebulo Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, meaning that its share price is 288% less volatile than the broader market.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

XBiotech's return on equity of -26.10% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

In the previous week, XBiotech had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for Anebulo Pharmaceuticals. XBiotech's average media sentiment score of 0.93 beat Anebulo Pharmaceuticals' score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Positive
Anebulo Pharmaceuticals	Neutral

55.7% of XBiotech shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

XBiotech beats Anebulo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to biote?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

biote has a consensus target price of $2.75, indicating a potential upside of 16.53%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

biote has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
biote	$192.22M	0.46	$27.05M	$0.44	5.36

Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its share price is 288% less volatile than the broader market. Comparatively, biote has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, biote had 3 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for biote and 0 mentions for Anebulo Pharmaceuticals. biote's average media sentiment score of 0.38 beat Anebulo Pharmaceuticals' score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
biote	Neutral

biote has a net margin of 8.29% compared to Anebulo Pharmaceuticals' net margin of 0.00%. biote's return on equity of -25.72% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
biote	8.29%	-25.72%	15.12%

Summary

biote beats Anebulo Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Acrivon Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Anebulo Pharmaceuticals has a beta of -1.88, indicating that its share price is 288% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Acrivon Therapeutics' average media sentiment score of 0.94 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Acrivon Therapeutics	Positive

Acrivon Therapeutics' return on equity of -64.43% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 652.69%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Acrivon Therapeutics beats Anebulo Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Annovis Bio had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Annovis Bio and 0 mentions for Anebulo Pharmaceuticals. Annovis Bio's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Annovis Bio	Neutral
Anebulo Pharmaceuticals	Neutral

Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Anebulo Pharmaceuticals' return on equity of -74.57% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Annovis Bio has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its stock price is 288% less volatile than the broader market.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Summary

Annovis Bio and Anebulo Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.31M	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-2.11	18.72	23.87	24.40
Price / Sales	N/A	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	1.43	6.80	9.99	6.73
Net Income	-$8.48M	$24.09M	$3.56B	$337.03M
7 Day Performance	-3.80%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-61.90%	48.95%	28.77%	34.24%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANEB Anebulo Pharmaceuticals	N/A	$0.40 +6.6%	N/A	-65.3%	$16.31M	N/A	N/A	4	Gap Up
MCRB Seres Therapeutics	2.0987 of 5 stars	$7.63 +0.5%	$22.00 +188.3%	+2.4%	$73.50M	$790K	N/A	330
XBIT XBiotech	0.6897 of 5 stars	$2.44 +1.7%	N/A	-17.3%	$73.17M	N/A	N/A	100
BTMD biote	3.5128 of 5 stars	$2.00 +4.2%	$2.75 +37.5%	-40.6%	$72.16M	$192.22M	4.36	194
ACRV Acrivon Therapeutics	2.3188 of 5 stars	$1.66 -0.6%	$11.67 +602.8%	+30.2%	$71.48M	N/A	N/A	58	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. MCRB, XBIT, BTMD, ACRV, and ANVS

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to XBiotech?

Summary

How does Anebulo Pharmaceuticals compare to biote?

Summary

How does Anebulo Pharmaceuticals compare to Acrivon Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Annovis Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. MCRB, XBIT, BTMD, ACRV, and ANVS

How does Anebulo Pharmaceuticals compare to Seres Therapeutics?

Which has more volatility and risk, ANEB or MCRB?

Is ANEB or MCRB more profitable?

Does the media refer more to ANEB or MCRB?

Do institutionals & insiders hold more shares of ANEB or MCRB?

Which has stronger valuation & earnings, ANEB or MCRB?

Do analysts prefer ANEB or MCRB?

Summary

How does Anebulo Pharmaceuticals compare to XBiotech?

Do analysts prefer XBIT or ANEB?

Which has more risk & volatility, XBIT or ANEB?

Which has preferable valuation and earnings, XBIT or ANEB?

Is XBIT or ANEB more profitable?

Does the media favor XBIT or ANEB?

Do insiders & institutionals believe in XBIT or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to biote?

Do analysts rate ANEB or BTMD?

Which has stronger valuation and earnings, ANEB or BTMD?

Which has more risk & volatility, ANEB or BTMD?

Do insiders & institutionals believe in ANEB or BTMD?

Does the media prefer ANEB or BTMD?

Is ANEB or BTMD more profitable?

Summary

How does Anebulo Pharmaceuticals compare to Acrivon Therapeutics?

Which has more volatility and risk, ANEB or ACRV?

Which has better earnings & valuation, ANEB or ACRV?

Do insiders & institutionals believe in ANEB or ACRV?

Does the media refer more to ANEB or ACRV?

Is ANEB or ACRV more profitable?

Do analysts rate ANEB or ACRV?

Summary

How does Anebulo Pharmaceuticals compare to Annovis Bio?

Do institutionals and insiders have more ownership in ANVS or ANEB?

Does the media favor ANVS or ANEB?

Do analysts prefer ANVS or ANEB?

Is ANVS or ANEB more profitable?

Which has more risk and volatility, ANVS or ANEB?

Which has stronger valuation & earnings, ANVS or ANEB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools